Outcomes and predicting response in anaemic chemotherapy patients treated with epoetin alfa. A multicentre, 4-month, open-label study in Australia and New Zealand

Internal Medicine Journal

Volumn 38, Issue 10, 2008, Pages 751-757

  Bell, D ^a   Grimes, D ^d   Gurney, H ^b   Dalley, D ^c   Blackwell, T ^e   Fox, R ^f   Jeffery, M ^g  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

^b WESTMEAD HOSPITAL   (Australia)

^c ST VINCENT S HOSPITAL   (Australia)

^d Brisbane Haematology Oncology Clinic   (Australia)

^e GREENSLOPES PRIVATE HOSPITAL   (Australia)

^f ST VINCENT S HOSPITAL   (Australia)

^g UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Anaemia; Cancer; Erythropoeitin

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; HEMOGLOBIN; IRON; IRON POLYMALTOSE; RECOMBINANT ERYTHROPOIETIN; TAXANE DERIVATIVE; VINCRISTINE;

ADULT; ANEMIA; ARTICLE; AUSTRALIA; BLOOD TRANSFUSION; CANCER CHEMOTHERAPY; CANCER PATIENT; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; EMOTION; ERYTHROCYTE COUNT; ERYTHROCYTE DISORDER; FATIGUE; FEMALE; HEMATOCRIT; HEMATOLOGIC DISEASE; HEMOGLOBIN BLOOD LEVEL; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NAUSEA; NEW ZEALAND; OPEN STUDY; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PHYSICAL CAPACITY; PRIORITY JOURNAL; QUALITY OF LIFE; RETICULOCYTE COUNT; SKIN DISEASE; SOMNOLENCE; THROMBOCYTOPATHY; THROMBOPHLEBITIS; THROMBOSIS; TREATMENT DURATION; URINARY TRACT DISEASE; WELLBEING;

AGED; AGED, 80 AND OVER; ANEMIA; ANTINEOPLASTIC AGENTS; AUSTRALIA; EPOETIN ALFA; FEMALE; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; NEW ZEALAND; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 55349089962     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2008.01736.x     Document Type: Article

References (15)

1. Engert A. Recombinant human erythropoietin in oncology: current status and further developments. Ann Oncol 2005 16 : 1584 95.
2. Ludwig H. Epoetin in cancer-related anaemia. Nephrol Dial Transplant 1999 14 Suppl 2 : 85 92.
3. Ross SD, Allen IE, Henry DH, Seaman C, Sercus B, Goodnough LT. Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: a systematic review of the literature. Clin Ther 2006 28 : 801 31.
4. Littlewood TJ, Zagari M, Pallister C, Perkins A. Baseline and early treatment factors are not clinically useful for predicting individual response to erythropoietin in anemic cancer patients. Oncologist 2003 8 : 99 107.
5. Henry D, Abels R, Larholt K. Prediction of response to recombinant human erythropoietin (r-HuEPO/epoetin-alpha) therapy in cancer patients. Blood 1995 85 : 1676 8.
6. Adamson JW, Ludwig H. Predicting the hematopoietic response to recombinant human erythropoietin (Epoetin alfa) in the treatment of the anemia of cancer. Oncology 1999 56 : 46 53.
7. Rizzo JD, Lichtin AE, Woolf SH, Seidenfeld J, Bennett CL, Cella D et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 2002 20 : 4083 107.
8. Bokemeyer C, Aapro MS, Courdi A, Foubert J, Link H, Osterborg A et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 2007 43 : 258 70.
9. FDA. Information for Healthcare Professionals Erythropoiesis Stimulating Agents (ESA). 2007. Available from : http://fda.gov/cder/drug/infosheets/HCP/ RHE2007HCP.htm
10. Bohlius J, Weingart O, Trelle S, Engert A. Cancer-related anemia and recombinant human erythropoietin - an updated overview. Nat Clin Pract Oncol 2006 3 : 152 64.
11. Bohlius J, Wilson J, Seidenfeld J, Piper M, Schwarzer G, Sandercock J et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 2006 98 : 708 14.
12. Bohlius J, Langensiepen S, Schwarzer G, Seidenfeld J, Piper M, Bennett C et al. Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. J Natl Cancer Inst 2005 97 : 489 98.
13. Bokemeyer C, Aapro MS, Courdi A, Foubert J, Link H, Osterborg A et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer 2004 40 : 2201 16.
14. Jones M, Schenkel B, Just J, Fallowfield L. Epoetin alfa improves quality of life in patients with cancer: results of meta analysis. Cancer 2004 101 : 1720 32.
15. Crawford J, Cella D, Cleeland CS, Cremieux PY, Demetri GD, Sarokhan BJ et al. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 2002 95 : 888 95.